Novo Nordisk A/S announced that its experimental drug CagriSema demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 clinical trial. The trial, which included 1,206 participants with a mean baseline body weight of 102 kg, showed that patients treated with CagriSema achieved a weight loss of 15.7% after 68 weeks, compared to 3.1% with placebo. After 68 weeks, 61.9% of patients were on the highest dose, and 89.7% of patients on CagriSema lost 5% or more of their body weight. Following the announcement of the trial results, shares of Novo Nordisk experienced a significant decline. The stock fell as much as 6.5%, marking the largest drop since December, despite the promising weight loss outcomes reported from the trial. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time. "The REDEFINE 2 results confirmed the superior efficacy of CagriSema in people with overweight or obesity and type 2 diabetes," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. Novo Nordisk plans to file for the first regulatory approval of CagriSema in the first quarter of 2026, indicating a potential future market entry for the drug.